Skip to main content

Ampicillin Disease Interactions

There are 5 disease interactions with ampicillin.

Major

Antibiotics (applies to ampicillin) colitis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious)

Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis. The most common culprits include clindamycin and lincomycin. Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development. Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea after antibacterial use. Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary. Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity. Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.

References

  1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
  2. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
  3. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
  4. "Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn (2002):
  5. "Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
  6. "Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals (2002):
  7. "Product Information. Amoxil (amoxicillin)." SmithKline Beecham (2001):
  8. "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals (2001):
  9. "Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis (2001):
  10. "Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn (2001):
  11. "Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc (2003):
  12. "Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals (2004):
  13. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical (2007):
  14. "Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc (2009):
  15. "Product Information. Vibativ (telavancin)." Theravance Inc (2009):
  16. "Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals (2010):
  17. "Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc (2022):
  18. "Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc. (2014):
  19. "Product Information. Orbactiv (oritavancin)." The Medicines Company (2014):
  20. "Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions (2017):
  21. "Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc. (2017):
  22. "Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC (2022):
  23. "Product Information. Zemdri (plazomicin)." Achaogen (2018):
  24. "Product Information. Seysara (sarecycline)." Allergan Inc (2018):
  25. "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc. (2018):
  26. "Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc. (2018):
  27. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
  28. "Product Information. Biaxin (clarithromycin)." AbbVie US LLC (2019):
  29. "Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group (2021):
  30. "Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals (2018):
  31. "Product Information. Priftin (rifapentine)." sanofi-aventis (2020):
View all 31 references
Moderate

Aminopenicillins (applies to ampicillin) mononucleosis

Moderate Potential Hazard, Moderate plausibility.

Patients with mononucleosis treated with an aminopenicillin antibiotic, may develop a pruritic erythematous maculopapular skin rash. The rash is usually self-limiting and resolves within days of discontinuing the offending agent. An altered drug metabolism or an immune-mediated process unrelated to drug hypersensitivity has been proposed as the underlying mechanism. Therapy with aminopenicillin antibiotics should not be administered in patients with mononucleosis.

References

  1. "Product Information. Polycillin-PRB (ampicillin-probenecid)." Apothecon Inc
  2. "Product Information. Spectrobid (bacampicillin)." Roerig Division (2002):
  3. "Product Information. Amoxil (amoxicillin)." SmithKline Beecham (2001):
Moderate

Ampicillin (applies to ampicillin) sodium

Moderate Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Fluid Retention, Hypertension, Hypernatremia

Parenteral ampicillin sodium contains approximately 67 to 71 mg (2.9 to 3.1 mEq) of sodium per each gram of ampicillin activity. The combination, ampicillin-sulbactam, contains approximately 115 mg (5 mEq) of sodium per 1.5 gram of total drug. The sodium content should be considered when these products are used in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.

References

  1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
  2. "Product Information. Unasyn (ampicillin-sulbactam)." Roerig Division (2002):
Moderate

Beta-lactams (parenteral) (applies to ampicillin) renal dysfunction

Moderate Potential Hazard, High plausibility.

Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites. The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function. Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents. Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling. Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.

References

  1. "Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories (2002):
  2. "Product Information. Ancef (cefazolin)." SmithKline Beecham (2002):
  3. "Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn (2002):
  4. "Product Information. Monocid (cefonicid)." SmithKline Beecham (2002):
  5. "Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel (2002):
  6. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals (2002):
  7. "Product Information. Mefoxin (cefoxitin)." Merck & Company Inc (2002):
  8. "Product Information. Fortaz (ceftazidime)." Glaxo Wellcome (2002):
  9. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham (2002):
  10. "Product Information. Cefizox (ceftizoxime)." Fujisawa (2002):
  11. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome (2002):
  12. "Product Information. Zinacef (cefuroxime)." Glaxo Wellcome (2002):
  13. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company (2002):
  14. "Product Information. Cefadyl (cephapirin)." Apothecon Inc (2002):
  15. "Product Information. Staphcillin (methicillin)." Apothecon Inc (2002):
  16. "Product Information. Pfizerpen (penicillin)." Roerig Division (2001):
  17. "Product Information. Pipracil (piperacillin)." Lederle Laboratories (2001):
  18. "Product Information. Ticar (ticarcillin)." SmithKline Beecham (2001):
  19. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company (2001):
  20. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb (2001):
  21. "Product Information. Fetroja (cefiderocol)." Shionogi USA Inc (2019):
View all 21 references
Moderate

Penicillins (applies to ampicillin) hemodialysis

Moderate Potential Hazard, High plausibility.

Penicillin antibiotics (except for agents in the penicillinase-resistant class) are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.

References

  1. Giron JA, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 19 (1981): 279-83
  2. Heim KL "The effect of hemodialysis on piperacillin pharmacokinetics." Drug Intell Clin Pharm 19 (1985): 455
  3. Francke EL, Appel GB, Neu HC "Kinetics of intravenous amoxicillin in patients on long-term dialysis." Clin Pharmacol Ther 26 (1979): 31-5
  4. Slaughter RL, Kohli R, Brass C "Effects of hemodialysis on the pharmacokinetics of amoxicillin/clavulanic acid combination." Ther Drug Monit 6 (1984): 424-7
  5. Janicke DM, Mangione A, Schultz RW, Jusko WJ "Mezlocillin disposition in chronic hemodialysis patients." Antimicrob Agents Chemother 20 (1981): 590-4
  6. Kampf D, Schurig R, Weihermuller K, Forster D "Effects of impaired renal function hemodialysis and peritoneal dialysis on the pharmacokinetics of mezlocillin." Antimicrob Agents Chemother 18 (1980): 81-7
  7. Davies BE, Boon R, Horton R, Reubi FC, Descoeudres CE "Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of augmentin." Br J Clin Pharmacol 26 (1988): 385-90
  8. Francke E, Mehta S, Neu HC, Appel GB "Kinetics of intravenous mezlocillin in chronic hemodialysis patients." Clin Pharmacol Ther 26 (1979): 228-31
  9. Thorsteinsson SB, Steingrimsson O, Asmundsson P, Bergan T "Pharmacokinetics of mezlocillin during haemodialysis." Scand J Infect Dis 29 (1981): 59-63
  10. Wise R, Reeves DS, Parker AS "Administration of ticarcillin, a new antipseudomonal antibiotic, in patients undergoing dialysis." Antimicrob Agents Chemother 5 (1974): 119-20
  11. Brogard JM, Comte F, Spach MO, Lavillaureix J "Pharmacokinetics of mezlocillin in patients with kidney impairment: special reference to hemodialysis and dosage adjustments in relation to renal function." Chemotherapy 28 (1982): 318-26
  12. Oe PL, Simonian S, Verhoef J "Pharmacokinetics of the new penicillins." Chemotherapy 19 (1973): 279-88
  13. Reitberg DP, Marble DA, Schultz RW, Whall TJ, Schentag JJ "Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother 32 (1988): 503-9
  14. Blum RA, Kohli RK, Harrison NJ, Schentag JJ "Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis." Antimicrob Agents Chemother 33 (1989): 1470-6
  15. Rho JP, Jones A, Wood M, et al. "Single-dose pharmacokinetics of intravenous ampicillin plus sulbactam in healthy elderly and young adult subjects." J Antimicrob Chemother 24 (1989): 573-80
  16. "Product Information. Polycillin-PRB (ampicillin-probenecid)." Apothecon Inc
  17. "Product Information. Spectrobid (bacampicillin)." Roerig Division (2002):
  18. "Product Information. Geocillin (carbenicillin)." Roerig Division (2002):
  19. "Product Information. Mezlin (mezlocillin)." Bayer (2002):
  20. "Product Information. Pfizerpen (penicillin)." Roerig Division (2001):
  21. "Product Information. Pipracil (piperacillin)." Lederle Laboratories (2001):
  22. "Product Information. Ticar (ticarcillin)." SmithKline Beecham (2001):
View all 22 references

Ampicillin drug interactions

There are 50 drug interactions with ampicillin.

Ampicillin alcohol/food interactions

There are 2 alcohol/food interactions with ampicillin.


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.